Clinical Trial Update: Efficacy of Type-5 Phosphodiesterase Inhibitors in Primary and Secondary Pulmonary Hypertension [NA]

View source ↗

Summary

This clinical trial evaluating Type-5 phosphodiesterase inhibitors for primary and secondary pulmonary hypertension has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Hypertension

Drugs mentioned

• Type-5 phosphodiesterase inhibitors

Snippet

Sponsor: National Taiwan University Hospital | Conditions: Primary and Secondary Pulmonary Hypertension | NA | Status: WITHDRAWN